Dr. Jose Martinez, General Practice Medicare: Not Enrolled in Medicare Practice Location: Barrio Jarealitos Calle Principal # 62, Arecibo, PR 00612 Phone: 787-878-3098 |
Emanuel Alvarez Rivera, MD General Practice Medicare: Medicare Enrolled Practice Location: 53 Ave Barbosa, Arecibo, PR 00612 Phone: 787-201-3113 Fax: 787-815-7953 |
Dr. Carlos R Rodriguez, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: Islote # 2 Casa # 102, Arecibo, PR 00612 Phone: 787-880-2517 Fax: 787-880-7818 |
Dr. Raphy Alexis Gonzalez, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: Carr #2 Km 65.6, Bo Factor 1, Arecibo, PR 00612 Phone: 787-881-2953 Fax: 787-881-4807 |
Mrs. Martha Iris Nieves, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: Carretera 635 Km 01, Sector Green Bo Dominguito, Arecibo, PR 00612 Phone: 787-878-7837 Fax: 787-878-7837 |
Adrian Romero Espinosa, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 55 Calle Palma, Arecibo, PR 00612 Phone: 502-424-6698 |
Daina I Antonsanti, MD General Practice Medicare: Medicare Enrolled Practice Location: Carr. #2 Bloque Mm Urb. Mirador Vista Azul, Arecibo, PR 00612 Phone: 787-613-9873 |
News Archive
Women who exercise and keep active are around 30 per cent less likely to develop womb cancer than couch potatoes - according to a new study published in the British Journal of Cancer today.
In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders.
ATENTIV, LLC, pioneers in digital therapies for Attention Deficit/Hyperactivity Disorder and other cognitive disorders, today announced the publication of a recently completed brain imaging study using the ATENTIVmynd Technology platform.
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
› Verified 1 days ago